Response-adapted therapy in melanoma, which involves removal of certain immunotherapeutic agents in a combination, can reduce costs without a decrease in efficacy, according to a study.
2022
How cancer cells can become immortal – new research finds a mutated gene that helps melanoma defeat the normal limits on repeated replication
A defining characteristic of cancer cells is their immortality. Usually, normal cells are limited in the number of times they can divide before they stop growing. Cancer cells, however, can overcome this limitation to form tumors and bypass “mortality” by continuing to replicate.
Dr. Carvajal on Unique Prognostic Factors in Uveal Melanoma
Richard D. Carvajal, MD, director, Experimental Therapeutics, director, the Melanoma Service, Columbia University Medical Center, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.
Evolving Immunotherapy Data Shed Light on Best Practices in Metastatic Melanoma
Different sequencing strategies may help improve outcomes and mitigate toxicities for patients with metastatic melanoma, according to Jeffrey S. Weber, MD, PhD.